Detailed price information for Sarepta Therapeutics (SRPT-Q) from The Globe and Mail including charting and trades.

Sarepta Therapeutics, Inc. faces setbacks with Elevidys, safety issues, and workforce cuts, raising concerns about its ...

The restructuring enacted by Sarepta Therapeutics is expected to save up to $400 million in annual costs. Read why I'm ...

Although Sarepta initially appeared to have avoided the worst possible outcome for Elevidys—market withdrawal—thanks to the gene therapy’s new black box warning, the FDA is signaling stronger ...

Though there were no historical benchmarks to gauge the response, the Dollar Index could fall more than 5%. Sterling edged higher versus the euro but remained weaker against a firmer dollar after the ...

The airline reset its profit guidance for the year, citing improved travel appetite after economic turmoil and flight disruptions depressed bookings this spring. Coca-Cola says more details are to ...

Sarepta Therapeutics appears to have right-sized itself after laying off over a third of its staff, announcing a significant ...

On an investor call Friday, analysts grilled the company over its apparent lack of transparency on the matter.

In a highly unusual move, Cambridge-based Sarepta said late Friday won’t comply with a request from the Food and Drug ...

Drugmaker Sarepta Therapeutics says it won’t comply with a request from U.S. regulators to halt all shipments of its gene ...

Analysts are intrested in these 5 stocks: ( ($JPM) ), ( ($SBUX) ), ( ($HPE) ), ( ($SRPT) ) and ( ($ELV) ). Here is a breakdown of their recent ...

Shares of Sarepta Therapeutics plummeted Friday following a report that a third patient has died during a clinical trial for ...